1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Charting the Global Biosimialr pipeline

Charting the Global Biosimialr pipeline

  • January 2018
  • ID: 5355975
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

There are multiple biosimilars in development for a range of therapy areas from cancer and diabetes to ophthalmology and respiratory. High-value mAbs such as Roche’s Avastin (bevacizumab), Abbvie’s Humira (adalimumab) and Janssen/Merck & Co’s Remicade (infliximab) are being targeted by multiple biosimilar developers. But which companies are leading the market? What products are being targeted? Where is development geographically concentrated? What licensing and collaboration opportunities are there?
The answers to these and many other questions can be found in Charting the Global Biosimilars Pipeline. This comprehensive report provides the most detailed evaluation of the biosimilar development landscape worldwide. Rich in tables, charts and statistics, it delivers the critical data you need to understand trends, identify opportunities and assess competitive threats.

Discover on this page…
• Why this report is important
• What the report can do for you
• Report contents

Why this report is important
What is the true potential of the much hyped biosimilar market? At present there are 260 biosimilar products which are approved in at least one market – and many of those are first generation products such as hormones. The future, however, is looking more interesting with 188 biosimilars in development, 61 of which are in Phase III trials. The number of high value mAbs for a wide range of conditions has increased. Development continues to be concentrated in countries such as India, China, Bangladesh, Iran and South Korea. In contrast, high development cost, originator defence strategies and more stringent regulatory regimes are pegging back development interest in the US and Europe. In the US there are 6 companies with 8 biosimilars registered . The sector is dominated by originator companies such as Pfizer, Amgen and Merck & Co. Europe is scarcely better with 9 companies and 13 biosimilars registered. The global biosimilar market is maturing both in its scope and ambitions.

Use this report to…
• Profile the most active biosimilar companies and their pipelines
• Know the development status of biosimilars targeting high-value brands and the companies that are involved
• Identify licensing and collaboration opportunities
• Assess the clinical trials that are underpinning biosimilar development
• Review 61 biosimilar projects in Phase III and anticipate where they will make a market impact
• Establish where biosimilar development around the world is concentrated and evaluate the companies driving progress

Report contents at a glance
This detailed 432 page report has been organised to give rapid access to, where relevant and available, the key information

Overview
• Biosimilars by therapy area
• Biosimilars by product class
• Most popular/bestselling biosimilar product candidates
• Biosimilars by development stage
• Leading biosimilar companies
• Biosimilar pipeline by product
BIOSIMILAR PIPELINE BY PRODUCT
Each biosimilar monograph utilises well-structured tables and charts to provide clear view of…

Details provided, where available
• Class
• Mode of action
• Key therapeutic area(s)
• Route of administration
• Reference product
• Originator
• RP sales
• RP indications
• US/EU patent information
• Number of companies developing this biosimilar
• Summary of biosimilar products in development by status, brand/lab code, company and location
• Biosimilar product approvals by territory, molecule, biosimilar company, approval date and biosimilar brand name
• Comprehensive summary of clinical trial activity including company, product code, trial code, phase, indication, patients enrolled, and estimated study completion dates

Products analysed
• Abatacept
• Abciximab
• Adalimumab
• Aflibercept
• Anakinra
• Bevacizumab
• Certolizumab Pegol
• Cetuximab
• Daclizumab
• Darbepoetin Alfa
• Denosumab
• Eculizumab
• Enoxaparin
• Epoetin Alfa
• Etanercept
• Filgrastim
• Follitropin Alfa
• Infliximab
• Insulin Aspart
• Insulin Glargine
• Insulin (Human)
• Insulin Lispro
• Interferon Alfa-2A
• Interferon Alfa-2B
• Interferon Beta-1A
• Interferon Beta-1B
• Interleukin-2
• Interleukin-11
• Omalizumab
• Palivizumab
• Pegfilgrastim
• Peginterferon Alfa-2A
• Peginterferon Alfa-2B
• Pertuzumab
• Ranibizumab
• Rituximab
• Somatropin
• Teriparatide
• Tocilizumab
• Trastuzumab
• Ustekinumab
• Vedolizumab

BIOSIMILAR PRODUCTS BY COMPANY
Each company monograph utilises well-structured tables and charts to provide, where relevant and available, a clear view of…

Details provided, where available
• Class
• Mode of action
• Key therapeutic area(s)
• Route of administration
• Reference product
• Originator
• RP sales
• RP indications
• US/EU Patent information
• Number of companies developing this biosimilar
• Biosimilar development status
• Biosimilar brand/lab code
• Biosimilar developer(s)
• Location of biosimilar developer(s)

Companies analysed
• Accord Healthcare
• Adello Biologics
• Alteogen
• Amgen
• Apotex
• Aprogen
• Archigen Biotech
• Biocad
• Biocon/Mylan
• Boehringer Ingelheim
• Celltrion
• Centus Biotherapeutics
• Cipla
• Coherus Biosciences
• Dem Ilaç
• Dr Reddy’s
• Epirus Biopharmaceuticals
• Finox Biotech
• Formycon AG
• Fresenius
• Fuji Pharma
• Fujifilm Kyowa Kirin Biologics
• Glenmark
• Hanwha Chemical
• Intas
• JCR Pharmaceuticals
• JHL Biotech
• LG Chem/LG Life Sciences
• Lilly
• Mabion
• mAbxience
• Merck & Co
• Mochida
• Momenta
• Nichi-Iko
• Nippon Kayaku
• Pfenex
• Pfizer
• Pharmathen
• Prestige Biopharma
• Reliance Life Sciences
• Rovi
• Samsung Bioepsis
• Sandoz
• Sanofi
• Stada Arzneimittel
• Techdow Europe AB
• Teva
• Torrent Pharmaceuticals
• USV
• Wockhardt
• YL Biologics
• Zydus Cadila

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Vascular Endothelial Growth Factor B - Pipeline Review, H1 2020

Vascular Endothelial Growth Factor B - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Vascular Endothelial Growth Factor B - Pipeline Review, H1 2020SummaryVascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is ...

Placenta Growth Factor - Pipeline Review, H2 2019

Placenta Growth Factor - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Placenta Growth Factor - Pipeline Review, H2 2019SummaryPlacenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 19 molecules. The latest ...

Post Menopausal Osteoporosis - Pipeline Review, H2 2019

Post Menopausal Osteoporosis - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Post Menopausal Osteoporosis - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2019, provides an overview ...


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on